<DOC>
	<DOCNO>NCT00004242</DOCNO>
	<brief_summary>Phase I trial study effectiveness combination chemotherapy treat patient metastatic unresectable solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , recommend phase II dose , associate toxic effect triple combination continuous infusion fluorouracil , weekly gemcitabine , oxaliplatin patient metastatic unresectable solid tumor . II . Define sequence dependent toxic effect , , establish pharmacokinetic pharmacodynamic relationship context triple combination chemotherapy patient population . OUTLINE : This dose-escalation study oxaliplatin gemcitabine . For course 1 , course 3 beyond , patient receive oxaliplatin IV 2 hour day 1 , follow gemcitabine IV 30 minute day 1 8 , fluorouracil IV continuously day 1-14 . For course 2 , patient receive treatment manner course 1 , except gemcitabine give initially , follow oxaliplatin , fluorouracil . Treatment continue every 21 day absence unacceptable toxicity disease progression . Cohorts 1-6 patient receive escalate dos oxaliplatin gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . The recommended phase II dose ( RPTD ) define dose precede MTD . Once RPTD define , cohort expand additional 13 patient . These patient receive fix dose oxaliplatin , gemcitabine , fluorouracil determine phase I dose escalation portion study . Patients follow disease progression .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically clinically confirm metastatic unresectable solid tumor standard curative palliative therapy exist long No know brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal Proven Gilbert 's syndrome ( UGT1A1 promoter mutation clinical documentation stress bilirubin level ) allow AST/ALT great 3 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Pulmonary : No unexplained respiratory problem ( e.g. , nonproductive cough , dyspnea , rale , pulmonary infiltrates , hypoxia , tachypnea ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinical evidence neuropathy No prior allergy platinum compound No prior allergy antiemetic appropriate administration conjunction protocol direct chemotherapy No concurrent uncontrolled illness ( e.g. , active infection ) PRIOR CONCURRENT THERAPY : Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas platinum ) recover No 1 prior chemotherapy regimen cancer Radiotherapy : At least 4 week since prior radiotherapy Other : No concurrent antiretroviral agent ( HAART ) No concurrent investigational agent commercial therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>